Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 7 de 7
Filter
Add more filters











Database
Language
Publication year range
1.
Biol Chem ; 397(4): 353-64, 2016 Apr.
Article in English | MEDLINE | ID: mdl-26669247

ABSTRACT

The bradykinin (BK) receptors B1R and B2R are involved in inflammatory responses and their activation can enhance tissue damage. The B2R is constitutively expressed and mediates the physiologic effects of BK, whereas B1R expression is induced after tissue damage. Recently, they have been involved with Alzheimer's disease, ischemic stroke and traumatic brain injury (TBI). In this study, we investigated the role of bradykinin in short and long-term memory consolidation (STM and LTM). It was observed that bilateral injection of BK (300 pmol/µl) disrupted the STM consolidation but not LTM, both evaluated by inhibitory avoidance test. The STM disruption due to BK injection was blocked by the previous injection of the B1R antagonist des-Arg10-HOE140 but not by the B2R antagonist HOE140. Additionally, the injection of the B1 agonist desArg9-BK disrupted STM and LTM consolidation at doses close to physiological concentration of the peptide (2.3 and 37.5 pmol, respectively) which could be reached during tissue injury. The presence of B1R located on glial cells around the implanted guide cannula used for peptide injection was confirmed by immunofluorescence. These data imply in a possible participation of B1R in the STM impairment observed in TBI, neuroinflammation and neurodegeneration.


Subject(s)
Hippocampus/metabolism , Memory Disorders/metabolism , Receptor, Bradykinin B1/metabolism , Animals , Hippocampus/pathology , Male , Memory Disorders/pathology , Memory Disorders/prevention & control , Rats , Rats, Wistar , Receptor, Bradykinin B1/administration & dosage
3.
PLoS One ; 10(11): e0142267, 2015.
Article in English | MEDLINE | ID: mdl-26605788

ABSTRACT

The use of lithium is well established in bipolar disorders and the benefits are being demonstrated in neurodegenerative disorders. Recently, our group showed that treatment with microdose lithium stabilized the cognitive deficits observed in Alzheimer's disease (AD) patients. In order to verify the lithium microdose potential in preventing the disease development, the aim of this work was to verify the effects of chronic treatment with microdose lithium given before and after the appearance of symptoms in a mouse model of a disease similar to AD. Transgenic mice (Cg-Tg(PDGFB-APPSwInd)20Lms/2J) and their non-transgenic litter mate genetic controls were treated with lithium carbonate (0.25mg/Kg/day in drinking water) for 16 or 8 months starting at two and ten months of age, respectively [corrected]. Similar groups were treated with water. At the end of treatments, both lithium treated transgenic groups and non-transgenic mice showed no memory disruption, different from what was observed in the water treated transgenic group. Transgenic mice treated with lithium since two months of age showed decreased number of senile plaques, no neuronal loss in cortex and hippocampus and increased BDNF density in cortex, when compared to non-treated transgenic mice. It is suitable to conclude that these data support the use of microdose lithium in the prevention and treatment of Alzheimer's disease, once the neurohistopathological characteristics of the disease were modified and the memory of transgenic animals was maintained.


Subject(s)
Alzheimer Disease/drug therapy , Amnesia/prevention & control , Cognition Disorders/prevention & control , Lithium Carbonate/pharmacology , Neuroprotective Agents/pharmacology , Plaque, Amyloid/prevention & control , Administration, Oral , Alzheimer Disease/genetics , Alzheimer Disease/pathology , Alzheimer Disease/physiopathology , Amnesia/genetics , Amnesia/pathology , Amnesia/physiopathology , Animals , Avoidance Learning/drug effects , Brain-Derived Neurotrophic Factor/genetics , Brain-Derived Neurotrophic Factor/metabolism , Cerebral Cortex/drug effects , Cerebral Cortex/pathology , Cerebral Cortex/physiopathology , Cognition Disorders/genetics , Cognition Disorders/pathology , Cognition Disorders/physiopathology , Disease Models, Animal , Drug Administration Schedule , Gene Expression , Hippocampus/drug effects , Hippocampus/pathology , Hippocampus/physiopathology , Humans , Locomotion/drug effects , Male , Maze Learning/drug effects , Memory/physiology , Mice , Mice, Transgenic , Plaque, Amyloid/genetics , Plaque, Amyloid/pathology , Plaque, Amyloid/physiopathology
4.
Curr Alzheimer Res ; 9(10): 1210-20, 2012 Dec.
Article in English | MEDLINE | ID: mdl-22515492

ABSTRACT

It is already known that progressive degeneration of cholinergic neurons in brain areas such as the hippocampus and the cortex leads to memory deficits, as observed in Alzheimer's disease. This work verified the effects of the infusion of amyloid-ß (Aß) peptide associated to an attentional rehearsal on the density of α7 nicotinic cholinergic receptor (nAChR) in the brain of male Wistar rats. Animals received intracerebroventricular infusion of Aß or vehicle (control - C) and their attention was stimulated weekly (Stimulated Aß group: S-Aß and Stimulated Control group: SC) or not (Non- Stimulated Aß group: N-SAß and Non-Stimulated Control group: N-SC), using an active avoidance apparatus. Conditioned avoidance responses (CAR) were registered. Chronic infusion of Aß caused a 37% reduction in CAR for N-SAß. In S-Aß, this reduction was not observed. At the end, brains were extracted and autoradiography for α7 nAChR was conducted using [125I]-α-bungarotoxin. There was an increase in α7 density in hippocampus, cortex and amygdala of SAß animals, together with the memory preservation. In recent findings from our lab using mice infused with Aß and the α7 antagonist methyllycaconitine, and stimulated weekly in the same apparatus, it was observed that memory maintenance was abolished. So, the increase in α7 density in brain areas related to memory might be related to a participation of this receptor in the long-lasting change in synaptic plasticity, which is important to improve and maintain memory consolidation.


Subject(s)
Amyloid beta-Peptides/pharmacology , Attention/drug effects , Brain/drug effects , Brain/metabolism , Peptide Fragments/pharmacology , Receptors, Nicotinic/metabolism , Analysis of Variance , Animals , Autoradiography , Avoidance Learning/drug effects , Bungarotoxins/pharmacokinetics , Humans , Iodine Isotopes/pharmacokinetics , Male , Protein Binding/drug effects , Rats , Rats, Wistar , Reaction Time/drug effects , Time Factors , alpha7 Nicotinic Acetylcholine Receptor
5.
Auton Neurosci ; 158(1-2): 71-8, 2010 Dec 08.
Article in English | MEDLINE | ID: mdl-20637711

ABSTRACT

Cardiovascular responses elicited by the stimulation of kinin B2 receptors in the IV cerebral ventricle, paratrigeminal nucleus or in the thoracic spinal cord are similar to those observed during an exercise bout. Considering that the kalikrein-kinin system (KKS) could act on the cardiovascular modulation during behavioral responses as physical exercise or stress, this study evaluated the central B2 receptor densities of Wistar (W) and spontaneously hypertensive rats (SHR) after chronic moderate exercise. Animals were exercise-trained for ten weeks on a treadmill. Afterwards, systolic blood pressure decreased in both trained strains. Animals were killed and the medulla and spinal cord extracted for B2 receptor autoradiography. Trained animals were compared to their sedentary controls. Sedentary groups showed specific binding sites for Hoe-140 (fmol/mg of tissue) in laminas 1 and 2 of the spinal cord, nucleus of the solitary tract (NTS), area postrema (AP), spinal trigeminal tract (sp5) and paratrigeminal nucleus (Pa5). In trained W a significant increase (p<0.05) in specific binding was observed in the Pa5 (31.3%) and NTS (28.2%). Trained SHR showed a significant decrease in receptor density in lamina 2 (21.9%) of the thoracic spinal cord and an increase in specific binding in Pa5 (36.1%). We suggest that in the medulla, chronic exercise could hyper stimulate the KKS enhancing their efficiency through the increase of B2 receptor density, involving this receptor in central cardiovascular control during exercise or stress. In the lamina 2, B2 receptor might be involved in the exercise-induced hypotension.


Subject(s)
Cerebral Ventricles/metabolism , Physical Conditioning, Animal/physiology , Receptor, Bradykinin B2/metabolism , Animals , Blood Pressure/physiology , Cerebral Ventricles/blood supply , Cerebral Ventricles/physiology , Kallikreins/physiology , Kinins/physiology , Male , Medulla Oblongata/blood supply , Medulla Oblongata/metabolism , Medulla Oblongata/physiology , Rats , Rats, Inbred SHR , Rats, Wistar , Receptor, Bradykinin B2/biosynthesis , Spinal Cord/blood supply , Spinal Cord/metabolism , Spinal Cord/physiology , Stress, Physiological , Time Factors , Up-Regulation/physiology
6.
Neuropeptides ; 44(2): 163-8, 2010 Apr.
Article in English | MEDLINE | ID: mdl-20060587

ABSTRACT

Under physiological conditions, elderly people present memory deficit associated with neuronal loss. This pattern is also associated with Alzheimer's disease but, in this case, in a dramatically intensified level. Kinin receptors have been involved in neurodegeneration and increase of amyloid-beta concentration, associated with Alzheimer's disease (AD). Considering these findings, this work evaluated the role of kinin receptors in memory consolidation during the aging process. Male C57Bl/6 (wt), knock-out B1 (koB1) or B2 (koB2) mice (3, 6, 12 and 18-month-old - mo; n=10 per group) were submitted to an acquisition session, reinforcement to learning (24h later: test 1) and final test (7days later: test 2), in an active avoidance apparatus, to evaluate memory. Conditioned avoidance responses (CAR, % of 50 trials) were registered. In acquisition sessions, similar CAR were obtained among age matched animals from all strains. However, a significant decrease in CAR was observed throughout the aging process (3mo: 8.8+/-2.3%; 6mo: 4.1+/-0.6%; 12mo: 2.2+/-0.6%, 18mo: 3.6+/-0.6%, P<0.01), indicating a reduction in the learning process. In test 1, as expected, memory retention increased significantly (P<0.05) in all 3- and 6-month-old animals as well as in 12-month-old-wt and 12-month-old-koB1 (P<0.01), compared to the training session. However, 12-month-old-koB2 and all 18-month-old animals did not show an increase in memory retention. In test 2, 3- and 6-month-old wt and koB1 mice of all ages showed a significant improvement in memory (P<0.05) compared to test 1. However, 12-month-old wt and koB2 mice of all ages showed no difference in memory retention. We suggest that, during the aging process, the B1 receptor could be involved in neurodegeneration and memory loss. Nevertheless, the B2 receptor is apparently acting as a neuroprotective factor.


Subject(s)
Aging/physiology , Avoidance Learning/physiology , Memory/physiology , Receptor, Bradykinin B1/physiology , Receptor, Bradykinin B2/physiology , Age Factors , Analysis of Variance , Animals , Exploratory Behavior/physiology , Male , Mice , Mice, Knockout , Motor Activity/physiology
7.
Neuropeptides ; 44(2): 93-7, 2010 Apr.
Article in English | MEDLINE | ID: mdl-19926131

ABSTRACT

Chronic infusion of human amyloid-beta 1-40 (Abeta) in the lateral ventricle (LV) of rats is associated with memory impairment and increase of kinin receptors in cortical and hippocampal areas. Deletion of kinin B1 or B2 receptors abolished memory impairment caused by an acute single injection of Abeta in the LV. As brain tissue and kinin receptors could unlikely react to acute or chronic administration of a similar quantity of Abeta, we evaluated the participation of B1 or B2 receptors in memory impairment after chronic infusion of Abeta. Male C57Bl/6J (wt), knock-out B1 (koB1) or B2 (koB2) mice (12weeks of age) previously trained in a two-way shuttle-box and achieving conditioned avoidance responses (CAR, % of 50 trials) were infused with AB (550pmol, 0.12microL/h, 28days) or vehicle in the LV using a mini-osmotic pump. They were tested before the surgery (T0), 7 and 35days after the infusion started (T7; T35). In T0, no difference was observed between CAR of the control (Cwt=59.7+/-6.7%; CkoB1=46.7+/-4.0%; CkoB2=64.4+/-5.8%) and Abeta (Abetawt=66.0+/-3.0%; AbetakoB1=66.8+/-8.2%; AbetakoB2=58.7+/-5.9%) groups. In T7, AbetakoB2 showed a significant decrease in CAR (41.0+/-8.6%) compared to the control-koB2 (72.8+/-2.2%, P<0.05). In T35, a significant decrease (P<0.05) was observed in Abetawt (40.7+/-3.3%) and AbetakoB2 (41.2+/-10.7%) but not in the AbetakoB1 (64.0+/-14.0%) compared to their control groups. No changes were observed in the controls at T35. We suggest that in chronic infusion of BA, B1 receptors could play an important role in the neurodegenerative process. Conversely, the premature memory impairment of koB2 suggests that it may be a protective factor.


Subject(s)
Amyloid beta-Peptides/administration & dosage , Avoidance Learning/physiology , Memory Disorders/metabolism , Memory/physiology , Peptide Fragments/administration & dosage , Receptor, Bradykinin B1/metabolism , Receptor, Bradykinin B2/metabolism , Analysis of Variance , Animals , Avoidance Learning/drug effects , Brain/metabolism , Male , Memory/drug effects , Mice , Mice, Knockout , Motor Activity/drug effects , Motor Activity/genetics , Neurons/metabolism , Receptor, Bradykinin B1/genetics , Receptor, Bradykinin B2/genetics
SELECTION OF CITATIONS
SEARCH DETAIL